Resiquimod: a new immune response modifier with potential as a vaccine adjuvant for Th1 immune responses.
about
Age-dependent maturation of Toll-like receptor-mediated cytokine responses in Gambian infantsImmunopathogenesis and therapy of cutaneous T cell lymphoma.Inhibiting the inhibitors: evaluating agents targeting cancer immunosuppression.An intranasally delivered Toll-like receptor 7 agonist elicits robust systemic and mucosal responses to Norwalk virus-like particles.The pharmacokinetics of Toll-like receptor agonists and the impact on the immune system.Preclinical evidence that PD1 blockade cooperates with cancer vaccine TEGVAX to elicit regression of established tumors.Host cell targets in HCV therapy: novel strategy or proven practice?Electrospray encapsulation of toll-like receptor agonist resiquimod in polymer microparticles for the treatment of visceral leishmaniasis.Mechanisms of action of adjuvantsAntigenic breadth: a missing ingredient in HSV-2 subunit vaccines?Toll-Like Receptor Agonists: Can They Exact a Toll on Human Immunodeficiency Virus Persistence?Differential gene expression following TLR stimulation in rag1-/- mutant zebrafish tissues and morphological descriptions of lymphocyte-like cell populationsR848, a toll-like receptor 7 agonist, inhibits osteoclast differentiation but not survival or bone-resorbing function of mature osteoclastsTLR7 ligand prevents allergen-induced airway hyperresponsiveness and eosinophilia in allergic asthma by a MYD88-dependent and MK2-independent pathway.
P2860
Q28741059-7898D73C-CE76-43DD-AAEA-151B42DB4343Q33726963-CC323BE8-BC57-4340-9787-9FD22C9ED626Q33903025-594882FA-92CA-40D4-90D5-BA3FB38B8024Q34431983-1952E1AC-6C41-4A69-A438-5451F01F80DBQ35018021-7F49EADF-583F-41EB-B236-96486560EE6CQ35412152-ED1B14A0-AFBA-48E9-BFC0-8C23EDC6A8FDQ36124729-8B184214-88EB-40F1-B0A1-1325A52108D5Q37378031-8247C9B5-73CC-4276-9A06-060B0AD05191Q38110539-BDB78808-4366-4DAF-88B0-C2205DE5774DQ38212516-8E87BE46-D50D-4ABD-81C1-258981AD2377Q40280210-B17A0CF7-B1F5-4EA7-9AEF-C31105D98421Q41073248-4C0BE312-79A9-4AEA-8571-6B4BF71BE268Q41827206-27498ED9-4BD0-4BBF-BA91-F42EB16F66FEQ46856473-A8F42CED-88C8-49DC-AB13-31082692F433
P2860
Resiquimod: a new immune response modifier with potential as a vaccine adjuvant for Th1 immune responses.
description
2004 nî lūn-bûn
@nan
2004 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Resiquimod: a new immune respo ...... vant for Th1 immune responses.
@ast
Resiquimod: a new immune respo ...... vant for Th1 immune responses.
@en
Resiquimod: a new immune respo ...... vant for Th1 immune responses.
@nl
type
label
Resiquimod: a new immune respo ...... vant for Th1 immune responses.
@ast
Resiquimod: a new immune respo ...... vant for Th1 immune responses.
@en
Resiquimod: a new immune respo ...... vant for Th1 immune responses.
@nl
prefLabel
Resiquimod: a new immune respo ...... vant for Th1 immune responses.
@ast
Resiquimod: a new immune respo ...... vant for Th1 immune responses.
@en
Resiquimod: a new immune respo ...... vant for Th1 immune responses.
@nl
P2093
P1433
P1476
Resiquimod: a new immune respo ...... vant for Th1 immune responses.
@en
P2093
David B Huang
Jashin J Wu
Stephen K Tyring
P356
10.1016/S0166-3542(04)00161-5
P577
2004-11-01T00:00:00Z